They're moving in on an aquisition. Mentioned it in an update last week. They just bought a ton of intellectual property from Cedars-Sinai and are adding at least 1 ph2 to their 2014 schedule. Same narrative - pathogen specific approach. Next year will be big year for them. They'll mature very quickly because they design rapid trials with extremely specific mechanisms of action and targets. So I'm loading.